Authors
Y-J Bang, E Yañez Ruiz, Eric Van Cutsem, K-W Lee, Lucjan Wyrwicz, Michael Schenker, Maria Alsina, M-H Ryu, H-C Chung, Ludovic Evesque, S-E Al-Batran, Se Hoon Park, Mikhail Lichinitser, Narikazu Boku, MH Moehler, Janet Hong, Huiling Xiong, Roland Hallwachs, Ilaria Conti, Julien Taieb
Publication date
2018/10/1
Journal
Annals of Oncology
Volume
29
Issue
10
Pages
2052-2060
Publisher
Elsevier
Description
Background
There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase III JAVELIN Gastric 300 trial compared avelumab versus physician’s choice of chemotherapy as third-line therapy in patients with advanced GC/GEJC.
Patients and methods
Patients with unresectable, recurrent, locally advanced, or metastatic GC/GEJC were recruited at 147 sites globally. All patients were randomised to receive either avelumab 10 mg/kg by intravenous infusion every 2 weeks or physician’s choice of chemotherapy (paclitaxel 80 mg/m2 on days 1, 8, and 15 or irinotecan 150 mg/m2 on days 1 and 15, each of a 4-week treatment cycle); patients ineligible for chemotherapy received best supportive care. The primary end point was overall survival (OS …
Scholar articles
YJ Bang, EY Ruiz, E Van Cutsem, KW Lee, L Wyrwicz… - Annals of Oncology, 2018